Phase Genomics’ Platform Links Viruses and Antibiotic Resistance Genes to the Microbiome in Study of a Highly Complex Microbial Community
06 août 2019 09h15 HE
|
Phase Genomics
SEATTLE, Washington, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the leading provider of proximity ligation next generation sequencing (NGS) solutions for genomics and metagenomics, in...
Skin health startup Derm-Biome Pharmaceuticals, Inc. to receive funding from the Government of Canada
09 juil. 2019 08h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, July 09, 2019 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals, Inc, a private Vancouver based start-up biopharmaceutical company focused on skin health, is excited to...
Phase Genomics Accelerates Microbiome Discovery and Antibiotic Resistance tracking with New ProxiMeta™ 8-Pack Including Bundled Analysis
20 juin 2019 09h05 HE
|
Phase Genomics
SEATTLE, Washington, June 20, 2019 (GLOBE NEWSWIRE) -- Phase Genomics, Inc., the biotech leader providing proximity ligation solutions for genome and metagenome assembly, announces its new...
Leading BioSciences to Present at Planet MicroCap Showcase 2019
25 avr. 2019 08h05 HE
|
Leading BioSciences
CARLSBAD, Calif., April 25, 2019 (GLOBE NEWSWIRE) -- Leading BioSciences, a drug development company focused on improving human health through therapeutic protection of the Gastrobiome™, today...
Taconic Biosciences Launches TruBIOME™ to Create Animal Models with Custom Microbiome Profiles
15 avr. 2019 09h00 HE
|
Taconic Biosciences
RENSSELAER, N.Y., April 15, 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces the launch of TruBIOMETM, a first of...
Taconic Biosciences Licenses the Wild Mouse Gut Microbiome from the National Institute of Diabetes and Digestive and Kidney Diseases
01 avr. 2019 11h43 HE
|
Taconic Biosciences
RENSSELAER, N.Y., April 01, 2019 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces it has obtained a license to the Wild...
MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis
20 mars 2019 19h55 HE
|
MatriSys Bioscience
SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin...
MatriSys Bioscience Appoints Jennifer Giottonini Cayer to Its Board of Directors
11 mars 2019 03h11 HE
|
MatriSys Bioscience
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience Inc., a clinical-stage specialty biopharmaceutical company developing microbiome-based therapies for the five most common skin...
Leading-Edge Microbiome Discovery Platform Receives New Funding
25 févr. 2019 09h17 HE
|
Phase Genomics
SEATTLE, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Phase Genomics, the leader in proximity ligation-based genomic solutions, announced today a year-long grant awarded by the Bill & Melinda Gates...
New Genomic Technology Advances Fight Against Global Health Threat of Antibiotic Resistance
06 déc. 2018 09h14 HE
|
Phase Genomics
SEATTLE, Dec. 06, 2018 (GLOBE NEWSWIRE) -- Phase Genomics, the leader in proximity-ligation genome assembly technology released an antimicrobial resistance (AMR) study led by researchers from the...